Current Status and Research Strategies in Tuberculosis Drug Development

ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTADDITION / CORRECTIONThis article has been corrected. View the notice.Current Status and Research Strategies in Tuberculosis Drug DevelopmentMiniperspectiveLynn G. Dover‡ and Geoffrey D. Coxon*†View Author Information† Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom‡ Biomolecular and Biomedical Research Centre, School of Life Sciences, Northumbria University, Newcastle upon Tyne, United KingdomPhone: +44(0)141 5485754. E-mail: [email protected]Cite this: J. Med. Chem. 2011, 54, 18, 6157–6165Publication Date (Web):August 8, 2011Publication History Received17 March 2011Published online16 August 2011Published inissue 22 September 2011https://pubs.acs.org/doi/10.1021/jm200305qhttps://doi.org/10.1021/jm200305qreview-articleACS PublicationsCopyright © 2011 American Chemical SocietyRequest reuse permissionsArticle Views6651Altmetric-Citations97LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Antimicrobial agents,Bacteria,Drug discovery,Infectious diseases,Pharmaceuticals Get e-Alerts